EvolveImmune Therapeutics

EvolveImmune Therapeutics has developed an immunobiology platform capable of delivering sustained immune activation and tumor cell targeting within a single therapeutic agent. By integrating signals, EVs represent the first biologics to directly target tumor cells and provide potent, tissue-localized amplification of cytokine secretion at the tumor site to maximize tumor killing. The company’s biologic therapies are designed to overcome the limitations of traditional CD3 bispecifics and other immunotherapies, offering a better future for patients in need by maximizing therapeutic benefits and minimizing toxicity.